Q&A Report: Dr. Rodrigo Burgos on Clinical Trial Diversity
![$acf['featured_image']['alt']](https://uniteus.com/wp-content/uploads/2023/04/QA-Preview-856x1024.png)
Life sciences organizations are increasingly aware of the powerful role drivers of health (DOH) play in whole-person care. However, it’s often a challenge for life sciences organizations to identify DOH needs for the communities they serve and to successfully factor them into research and development efforts. Clinical trial diversity, in particular, has remained both a pressing challenge and a key priority.
By filling out this form, I agree to Unite Us’ Privacy Policy.
We interviewed industry expert Dr. Rodrigo Burgos, Clinical Assistant Professor and HIV PGY-2 Residency Co-Director at the University of Illinois Chicago, to share his thoughts on the evolving matter of clinical trial diversity. As an HIV pharmacotherapy specialist and pharmacy residency director, Dr. Burgos is committed to expanding opportunities to support pharmacists who serve marginalized communities.
Read the Q&A report to learn more.